Currently out of the existing stock ratings of Tessa Romero, 84 are a BUY (73.04%), 28 are a HOLD (24.35%), 3 are a SELL (2.61%).

Tessa Romero

Work Performance Price Targets & Ratings Chart

Analyst Tessa Romero, currently employed at JPMORGAN, carries an average stock price target met ratio of 48.27% that have a potential upside of 40.76% achieved within 130 days.

Tessa Romero’s has documented 222 price targets and ratings displayed on 19 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on LXEO, Lexeo Therapeutics, Common Stock at 25-Jun-2026.

Wall Street Analyst Tessa Romero

Analyst best performing recommendations are on SRRK (SCHOLAR ROCK HOLDING CORP).
The best stock recommendation documented was for SRRK (SCHOLAR ROCK HOLDING CORP) at 10/3/2024. The price target of $18 was fulfilled within 4 days with a profit of $10.93 (154.6%) receiving and performance score of 386.49.

Average potential price target upside

of $20.2 (56.09%) on XENE (XENON PHARMACEUTICALS).
of $14.86 (124.13%) on EWTX (EDGEWISE THERAPEUTICS).
of $14.46 (33.31%) on CYTK (CYTOKINETICS).

EWTX Edgewise Therapeutics GBT Global Blood Therapeutics ORTX Orchard Therapeutics PLC ATRA Atara Biotherapeutics RIGL Rigel Pharmaceuticals SRRK Scholar Rock Holding Corp YMAB Y mAbs Therapeutics CYTK Cytokinetics XENE Xenon Pharmaceuticals ACAD ACADIA Pharmaceuticals BHVN Biohaven Pharmaceutical Holding Co Ltd AGIO Agios Pharm DYN Dyne Therapeutics EYPT Eyepoint Pharmaceuticals MCRB Seres Therapeutics NMRA Neumora Therapeutics GBTG Global Business Travel Group LXEO Lexeo Therapeutics, Common Stock SANA Sana Biotechnology

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Leonid Timashev (RBC)